Which has better earnings and valuation, DXCM or HQY?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.75 $836.30M $2.53 32.98 HealthEquity $1.31B 6.40 $215.20M $2.67 37.68

Is DXCM or HQY more profitable?

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% HealthEquity 17.25% 14.75% 9.22%

Does the media favor DXCM or HQY?

In the previous week, DexCom had 45 more articles in the media than HealthEquity. MarketBeat recorded 53 mentions for DexCom and 8 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.74 beat DexCom's score of 0.92 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, DXCM or PODD?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.75 $836.30M $2.53 32.98 Insulet $2.71B 4.23 $247.10M $4.30 38.45

Is DXCM or PODD more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Insulet 10.44% 26.87% 12.01%

Does the media favor DXCM or PODD?

In the previous week, DexCom had 9 more articles in the media than Insulet. MarketBeat recorded 53 mentions for DexCom and 44 mentions for Insulet. DexCom's average media sentiment score of 0.92 beat Insulet's score of 0.46 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 14 Very Positive mention(s) 2 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abbott Laboratories $44.33B 4.14 $6.52B $3.09 34.30 DexCom $4.66B 6.75 $836.30M $2.53 32.98

Does the media prefer ABT or DXCM?

In the previous week, Abbott Laboratories had 3 more articles in the media than DexCom. MarketBeat recorded 56 mentions for Abbott Laboratories and 53 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.11 beat DexCom's score of 0.92 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 38 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMN or DXCM?

In the previous week, DexCom had 44 more articles in the media than AMN Healthcare Services. MarketBeat recorded 53 mentions for DexCom and 9 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 0.92 beat AMN Healthcare Services' score of 0.83 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ITGR or DXCM?

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.22 $102.81M $4.01 30.19 DexCom $4.66B 6.75 $836.30M $2.53 32.98

Is ITGR or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Integer's net margin of 7.64%. DexCom's return on equity of 35.94% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% DexCom 20.12% 35.94% 14.75%

Does the media prefer ITGR or DXCM?

In the previous week, DexCom had 38 more articles in the media than Integer. MarketBeat recorded 53 mentions for DexCom and 15 mentions for Integer. DexCom's average media sentiment score of 0.92 beat Integer's score of 0.81 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 4 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DexCom (DXCM) Competitors

$83.45 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$82.74 -0.71 (-0.85%)

As of 07/31/2026 07:59 PM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? MarketBeat compares DexCom with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR).

How does DexCom compare to HealthEquity?

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 1.6% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

DexCom currently has a consensus target price of $88.13, suggesting a potential upside of 5.60%. HealthEquity has a consensus target price of $110.93, suggesting a potential upside of 10.26%. Given HealthEquity's higher probable upside, analysts plainly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, DexCom had 45 more articles in the media than HealthEquity. MarketBeat recorded 53 mentions for DexCom and 8 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.74 beat DexCom's score of 0.92 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
HealthEquity	17.25%	14.75%	9.22%

DexCom has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, HealthEquity has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98
HealthEquity	$1.31B	6.40	$215.20M	$2.67	37.68

Summary

DexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

DexCom has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Insulet has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

DexCom currently has a consensus target price of $88.13, indicating a potential upside of 5.60%. Insulet has a consensus target price of $233.38, indicating a potential upside of 41.14%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
Insulet	2 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.68

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98
Insulet	$2.71B	4.23	$247.10M	$4.30	38.45

In the previous week, DexCom had 9 more articles in the media than Insulet. MarketBeat recorded 53 mentions for DexCom and 44 mentions for Insulet. DexCom's average media sentiment score of 0.92 beat Insulet's score of 0.46 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	14 Very Positive mention(s)	2 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DexCom has a net margin of 20.12% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Insulet	10.44%	26.87%	12.01%

97.8% of DexCom shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.4% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

DexCom beats Insulet on 12 of the 16 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Abbott Laboratories had 3 more articles in the media than DexCom. MarketBeat recorded 56 mentions for Abbott Laboratories and 53 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.11 beat DexCom's score of 0.92 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	38 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	4.14	$6.52B	$3.09	34.30
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98

DexCom has a net margin of 20.12% compared to Abbott Laboratories' net margin of 11.65%. DexCom's return on equity of 35.94% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	11.65%	17.69%	9.44%
DexCom	20.12%	35.94%	14.75%

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Abbott Laboratories has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

Abbott Laboratories presently has a consensus price target of $118.17, suggesting a potential upside of 11.50%. DexCom has a consensus price target of $88.13, suggesting a potential upside of 5.60%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, equities research analysts clearly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Abbott Laboratories beats DexCom on 10 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.48	-$95.70M	-$0.87	N/A
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98

In the previous week, DexCom had 44 more articles in the media than AMN Healthcare Services. MarketBeat recorded 53 mentions for DexCom and 9 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 0.92 beat AMN Healthcare Services' score of 0.83 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

AMN Healthcare Services currently has a consensus target price of $29.00, suggesting a potential downside of 14.05%. DexCom has a consensus target price of $88.13, suggesting a potential upside of 5.60%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has a net margin of 20.12% compared to AMN Healthcare Services' net margin of -0.95%. DexCom's return on equity of 35.94% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
DexCom	20.12%	35.94%	14.75%

Summary

DexCom beats AMN Healthcare Services on 15 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Integer has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

99.3% of Integer shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to Integer's net margin of 7.64%. DexCom's return on equity of 35.94% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
DexCom	20.12%	35.94%	14.75%

Integer currently has a consensus price target of $97.00, indicating a potential downside of 19.88%. DexCom has a consensus price target of $88.13, indicating a potential upside of 5.60%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.22	$102.81M	$4.01	30.19
DexCom	$4.66B	6.75	$836.30M	$2.53	32.98

In the previous week, DexCom had 38 more articles in the media than Integer. MarketBeat recorded 53 mentions for DexCom and 15 mentions for Integer. DexCom's average media sentiment score of 0.92 beat Integer's score of 0.81 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	4 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Integer on 14 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.49B	$5.58B	$6.86B	$12.42B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	32.98	23.11	282.27	24.66
Price / Sales	6.75	56.61	590.91	92.54
Price / Cash	30.14	32.53	28.60	46.71
Price / Book	11.85	6.29	10.93	6.07
Net Income	$836.30M	$151.15M	$3.49B	$347.99M
7 Day Performance	13.74%	1.01%	-0.64%	-0.42%
1 Month Performance	17.12%	4.43%	-3.78%	-4.80%
1 Year Performance	5.26%	2.35%	61.99%	18.61%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	3.896 of 5 stars	$83.45 flat	$88.13 +5.6%	+5.3%	$31.49B	$4.66B	32.98	11,000	Trending News Earnings Report Analyst Forecast Gap Down High Trading Volume
HQY HealthEquity	4.0882 of 5 stars	$99.05 +4.7%	$110.93 +12.0%	+10.5%	$8.28B	$1.31B	37.10	2,814	Positive News
PODD Insulet	4.7133 of 5 stars	$165.00 +1.1%	$235.25 +42.6%	-42.0%	$11.43B	$2.71B	38.37	5,400	Trending News Upcoming Earnings Analyst Upgrade
ABT Abbott Laboratories	4.5788 of 5 stars	$104.61 +1.5%	$118.61 +13.4%	-16.8%	$182.20B	$44.33B	33.85	115,000	Trending News Analyst Forecast Analyst Revision
AMN AMN Healthcare Services	1.9281 of 5 stars	$33.31 +1.3%	$29.00 -12.9%	+89.3%	$1.29B	$2.73B	N/A	2,664	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors